Novocure

Novocure, founded in 2000, is a global oncology company dedicated to extending survival for patients with some of the most aggressive forms of cancer. The company's core innovation is Tumor Treating Fields (TTFields), a novel therapeutic approach that utilizes electric fields to disrupt cancer cell division. Novocure is actively commercializing its TTFields therapy, which has received approvals in specific countries for treating adult patients with glioblastoma and in the U.S. for malignant pleural mesothelioma. The company operates within the Pharmaceuticals and Healthcare industries, focusing on developing and delivering advanced cancer care solutions.

With a global presence, Novocure employs between 1,000 and 5,000 individuals across its operations. The company maintains a count of 4 primary locations, with offices strategically situated in Germany, Switzerland, Japan, and Israel, in addition to its U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. This expansive operational footprint supports its mission to bring TTFields therapy to patients worldwide. To learn more about the people driving this innovation, Meet Novocure's team for insights into their leadership and expertise.

Novocure is committed to advancing cancer treatment through extensive research and development, with ongoing or completed clinical trials investigating TTFields across a range of indications including brain metastases, gastric cancer, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company reported a revenue of $674.4M. Its financial history includes significant funding rounds, such as debt financing and stock issuances, underscoring investor confidence in its therapeutic platform. For detailed financial performance and investment information, Explore financialView more...